Abstract Metamorphosis, the transformation of one normal tissue or organ system into another, is a biological process rarely studied in higher vertebrates or mammals, but exemplifi ed pathologically by the extremely disabling autosomal dominant disorder fi brodysplasia ossifi cans progressiva (FOP). The recurrent single nucleotide missense mutation in the gene encoding activin receptor IA/activin-like kinase-2 (ACVR1/ALK2), a bone morphogenetic protein type I receptor that causes skeletal metamorphosis in all classically affected individuals worldwide, is the fi rst identifi ed human metamorphogene. Physiological studies of this metamorphogene are beginning to provide deep insight into a highly conserved signaling pathway that regulates tissue stability following morphogenesis, and that when damaged at a highly specifi c locus (c.617G > A; R206H), and triggered by an infl ammatory stimulus permits the renegade metamorphosis of normal functioning connective tissue into a highly ramifi ed skeleton of heterotopic bone. A comprehensive understanding of the process of skeletal metamorphosis, as revealed by the rare condition FOP, will lead to the development of more effective treatments for FOP and, possibly, for more common disorders of skeletal metamorphosis.
Introduction
Cancer, aging, degeneration, infl ammation, and repair are well-known tissue processes that have received enormous attention in the scientifi c and medical literature. In contrast, the process of metamorphosis, the transformation of one normal tissue or organ system into another through a pathological process, is virtually unexplored and has been hidden for centuries behind the mask of an exceedingly rare and catastrophic human disease, fi brodysplasia ossifi cans progressiva (FOP). The genetic and molecular lessons of FOP are rapidly being revealed and its importance to medicine far exceeds its rarity [1] .
Clinical features of FOP
Two clinical features defi ne classic FOP: congenital malformation of the great toes and progressive heterotopic ossification in distinct anatomic patterns ( Fig. 1) [2] . Individuals with FOP appear normal at birth except for malformations of the great toes, which are present in 100% of classically affected individuals [3] . During the fi rst decade of life, children with FOP develop painful and highly infl ammatory soft tissue swellings (or fl are-ups) that progressively and permanently transform soft connective tissues, including aponeuroses, fascia, ligaments, tendons, and skeletal muscles, into an armament-like encasement of heterotopic bone [4, 5] . Ribbons, sheets, and plates of heterotopic bone replace skeletal muscles and connective tissues through a process of endochondral ossifi cation that leads to the formation of a highly ramifi ed second skeleton with resultant permanent immobility [6] [7] [8] [9] . Minor trauma such as intramuscular immunizations, mandibular blocks for dental work, muscle fatigue, blunt muscle trauma from bumps, bruises, falls, or infl uenza-like illnesses can trigger painful new fl are-ups of FOP, leading to progressive heterotopic ossifi cation (HO) [10] [11] [12] [13] [14] .
Surgical attempts to operatively remove heterotopic bone commonly lead to episodes of explosive and painful new bone growth [15] [16] [17] [18] [19] . HO in FOP progresses in characteristic anatomic and temporal patterns that mimic the patterns of normal embryonic skeletal formation. FOP involvement typically is seen fi rst in the dorsal, axial, cranial, and proximal regions of the body and later in the ventral, appendicular, caudal, and distal regions [2, 4, 5, 15, 17] . Several skeletal muscles including the diaphragm, tongue, and extraocular muscles are enigmatically spared from FOP. Cardiac muscle and smooth muscle are not involved in the FOP process [2, [15] [16] [17] .
The clinical features of early lesional involvement in the axial regions are often different from those seen in the appendicular regions [20] . New lesions may appear rapidly. In the axial regions, swelling is often mistaken for tumors, as large bulbous lesional swellings may appear on the neck and back, whereas in the limbs, the swelling is often diffuse, and may be mistaken for acute thrombophlebitis, a complication that can occur in patients with FOP as a result of generalized immobility and associated venous stasis [20] . The qualitative differences in swelling in the axial versus the appendicular regions in patients with FOP may refl ect regional differences in the anatomy of the subaponeurotic spaces as well as differences in the anatomy of the fascial compartments.
Bone formation in FOP is episodic, but disability is cumulative. Most patients with FOP are confi ned to a wheelchair by the third decade of life and require lifelong assistance in performing activities of daily living [2, [15] [16] [17] [18] [19] . Severe weight loss may result from ankylosis of the jaw, and pneumonia or right-sided heart failure may complicate rigid fi xation of the chest wall [21] . The severe disability of FOP results in low reproductive fi tness, and fewer than ten multigenerational families are known worldwide [22] . The median age of survival is approximately 41 years, and death often results from complications of thoracic insuffi ciency syndrome [21] .
Diagnosis and misdiagnosis of FOP
FOP is commonly misdiagnosed, as clinicians often fail to associate the rapidly developing soft tissue swellings that appear on the head, neck, and upper back with the malformed great toes [23] . FOP can be diagnosed clinically even before radiographic evidence of heterotopic ossifi cation is seen if rapidly waxing and waning soft tissue lesions are associated with symmetrical malformations of the great toes [24] . When such associations are not made, FOP is commonly misdiagnosed as aggressive juvenile fi bromatosis (extraabdominal desmoid tumors), lymphedema, or soft tissue sarcomas. Children often undergo unnecessary and harmful diagnostic biopsies that exacerbate the progression of the condition [23] .
Additional skeletal anomalies in FOP
In addition to malformations of great toes and thumbs, early developmental anomalies are frequently observed in the cervical spine [25] . Stiffness of the neck is an early fi nding in most patients and can precede the appearance of HO. Characteristic anomalies of the cervical spine include large posterior elements, tall narrow vertebral bodies, and fusion of the facet joints between C2 and C7, fi ndings that are strikingly similar to those seen in mice with homozygous deletions of the gene encoding Noggin, a secreted bone morphogenetic protein (BMP) antagonist [26] , supporting that increased BMP pathway signaling underlies the disease [25] . Although mutations in the Noggin gene have been reported [27] [28] [29] , these fi ndings could not be reconfi rmed and are thought to be in error [30] [31] [32] [33] [34] .
Other skeletal anomalies often associated with FOP include short malformed thumbs, clinodactyly, short broad femoral necks, and proximal medial tibial osteochondromas. The latter two fi ndings are also seen in patients who have multiple hereditary exostoses (MHE), although the genes associated with multiple hereditary exostoses are not mutated in patients who have FOP. Nevertheless, these shared clinical fi ndings may illuminate common pathway anomalies [2, [15] [16] [17] 35] .
Epidemiological, genetic, and environmental factors in FOP FOP is extremely rare, with a worldwide prevalence of approximately 1 in 2 million. There is no ethnic, racial, gender, or geographic predisposition [17, 19] . Most cases arise as a result of a spontaneous new mutation. When observed, genetic transmission is autosomal dominant and can be inherited from either mothers or fathers [22, 36] .
Both genetic and environmental factors affect the phenotype of FOP. A study of three pairs of monozygotic twins with FOP found that, within each pair, congenital great toe malformations were identical. However, postnatal heterotopic ossifi cation varied greatly depending on life history and environmental exposure. This study indicated that genetic determinants strongly infl uence disease phenotype during prenatal development and that environmental factors strongly infl uence postnatal progression of heterotopic ossifi cation [37] .
The pathobiology of skeletal metamorphosis in FOP
The process of skeletal metamorphosis, as exemplifi ed by FOP, does not involve the transdifferentiation of one mature cell into another, but rather a pathological process in which the normal structure and function of one tissue or organ are destroyed and replaced by those of another functioning tissue or organ [9, 38] .
The pathological stages of skeletal metamorphosis have been well described in FOP and correspond to the BMPinduced lesions described in several reports [6] [7] [8] [39] [40] [41] [42] [43] [44] . Skeletal metamorphosis in FOP begins with a soft tissue injury that triggers an infl ammatory infi ltrate and proceeds to muscle cell injury and death, replacement with a highly angiogenic fi broproliferative lesion, and maturation through a cartilage anlagen that culminates in the formation of a new skeletal element [6] [7] [8] [9] [38] [39] [40] [41] [42] [43] [44] .
Despite detailed descriptions of FOP pathology in the medical literature, there has been a persistent misconception in the medical and scientifi c community about the process. For example, it is commonly believed that the process of skeletal metamorphosis involves a transdifferentiation of mature muscles cells into bone cells. That, in fact, does not appear to occur in vivo. Studies by Katagiri and colleagues have documented that C2C12 myoblasts, which are believed to be derived from satellite cells in murine thigh muscle, can express an osteogenic phenotype in the presence of high concentrations of recombinant BMP or constitutively active BMP type I receptors in vitro, and provide the template for understanding how dysregulation of the BMP signaling pathway can lead to altered progenitor cell fates [45, 46] . Thus, mature muscles cells including myofi bers do not transdifferentiate into mature bone cells. Rather, normal muscle tissue is replaced by normal bone tissue in a complex pathological process of skeletal metamorphosis that involves the epigenetic reprogramming of progenitor cell fates.
Morphogen receptor genes
The bone morphogenetic protein (BMP) signaling pathway is one of the most highly conserved signaling pathways in nature and regulates a myriad of developmental and postdevelopmental processes beginning in early embryogenesis and continuing through adult life [41, [47] [48] [49] [50] [51] [52] [53] [54] . A large body of evidence supports that BMPs act as morphogens in vertebrate development [41, [51] [52] [53] [54] [55] . BMPs signal by binding to and activating heterotetrameric transmembrane complexes of type I and type II BMP receptors. Both type I and type II BMP receptors are serine/threonine kinases that have similar functional domains. Ligand binding occurs preferentially at the N-terminal extracellular domain of the BMP receptors, which is connected by a single transmembrane region to the C-terminal cytoplasmic kinase domain [51] [52] [53] [54] . BMP signaling can be mediated by four known type I receptors: TSR (ALK1), ACVR1 (ALK2), BMPR1A (ALK3), and BMPR1B (ALK6). A unique feature of type I receptors is a cytoplasmic juxtamembrane region rich in glycine and serine residues (GS domain). Following ligand binding, serines and threonines in the GS domain are phosphorylated by the constitutively active BMP type II receptor. The BMP type I receptor is activated by these phosphorylation events and transmits downstream BMP signals through BMP pathway-specifi c Smads (Smads1, −5, −8) and p38 MAPK signaling pathways to regulate transcription of BMP-responsive target genes. Numerous comprehensive reviews are available on this seminal signaling pathway that will orient the reader to the concepts which follow here [51] [52] [53] [54] .
Discovery of the FOP metamorphogene
A large body of work has supported dysregulated BMP signaling in the pathogenesis of FOP [56] [57] [58] [59] [60] [61] [62] [63] . FOP was recently mapped to chromosome 2q23-24 by genome-wide linkage analysis, a region that includes the ACVR1 gene. ACVR1/ALK2 is one of seven activin-like kinases (ALKs) in the human genome that all encode transforming growth factor-beta (TGF-β)/BMP type I serine/threonine transmembrane receptors involved in the specifi cation of cell fate and differentiation in a wide variety of cells and tissues during embryonic development and postnatal life [64] . In all classically affected individuals worldwide, an identical heterozygous missense activating mutation (c.617G > A; R206H) was subsequently identifi ed in the glycine-serine (GS) activation domain of ACVR1 [3] .
This single nucleotide missense mutation transforms a morphogen receptor gene into a metamorphogene. The resultant mutant protein alters the basal set point and ligand-dependent sensitivity for BMP signaling in a cellautonomous manner in connective tissue progenitor cells [63] . Identifi cation of the mutant transmembrane receptor (and remarkably a single substituted amino acid residue in that receptor) provides a basis for elucidating the molecular pathophysiology of dysregulated BMP signaling and resultant skeletal metamorphosis in this illustrative and disabling condition [3, 63] .
Although ACVR1/ALK2 has been recognized as a BMP receptor, investigations of its functions in embryonic development and in regulating cell differentiation have been limited [3] . ACVR1/ALK2 is expressed in many tissues including skeletal muscle and chondrocytes. Constitutive activation of ACVR1/ALK2 induces alkaline phosphatase activity in C2C12 cells, upregulates BMP4, downregulates BMP antagonists, expands cartilage elements, induces ectopic chondrogenesis, and stimulates joint fusions, fi ndings nearly identical to those seen in FOP [65] . Constitutive ACVR1/ALK2 expression (similar to that seen in FOP) in embryonic chick limbs induces expansion of chondrogenic anlage and induces joint fusions, suggesting that promiscuous ACVR1/ALK2 signaling alters cell fate and induces undifferentiated mesenchyme to form cartilage and bone [65] . Enhanced ACVR1/ALK2 activation in FOP is supported by recent data showing increased pathway-specifi c Smad phosphorylation and expression of BMP transcriptional targets in FOP cells as well as reversal of an ACVR1/ ALK2-homologue loss of function phenotype by the ACVR1 (FOP) construct in mutant zebrafi sh embryos [66, 67] .
Protein homology mapping of mutant ACVR1
Protein homology modeling of the mutant ACVR1/ALK2 in FOP predicts changes in both ligand-independent BMP signaling and in ligand-stimulated BMP signaling in FOP cells [68] . We hypothesize that the canonical FOP mutation (ACVR1 c.617G>A; R206H), which replaces an arginine
The GS domain of all TGF-β BMP type I receptors is a critical site for activation of pathway-specifi c Smad signaling proteins by constitutively active TFG-β/BMP type II receptors [69] [70] [71] [72] . FKBP12 binds and stabilizes the inactive confi rmation of all type I TGF-β/BMP receptors including ACVR1/ALK2. When bound to the GS domain, FKBP12 prevents leaky activation of type I receptors in the absence of ligand [69] [70] [71] [72] . Importantly, FKBP12 also serves as a docking protein for the Smad-Smurf complexes that mediate ubiquitination, internalization, and degradation of ACVR1/ALK2, and is predicted to regulate the concentration of ACVR1/ALK2 and its BMP type I receptor oligomerization partners at the cell membrane [73, 74] .
The FOP mutation is predicted to impair FKBP12 binding and/or activity with resultant increased basal activity of BMP signaling in the absence of ligand as well as hyper-responsiveness of BMP signaling following ligand binding, two features of BMP signal dysregulation that have recently been demonstrated in FOP cells [63] . Thus, one scenario is that FKBP12 interaction with the GS domain may be altered in FOP, leading to promiscuous ACVR1/ ALK2 activity (Fig. 2) . Recent preliminary data strongly support this hypothesis, and it is the subject of intensive investigation.
The immune system and metamorphosis in FOP
Although dysregulation of the BMP signaling pathway can explain many features of skeletal metamorphosis in FOP, other features of the disease strongly implicate an underlying infl ammatory trigger and/or a conducive infl ammatory microenvironment [75] (Fig. 3) .
A recent study showed that aberrant expression of BMPs in soft tissue causes focal hypoxia and hypoxic stress within the target tissue, a prerequisite for the differentiation of stem cells to chondrocytes and subsequent formation of heterotopic bone [76] . Flare-ups of FOP are frequently associated with muscle fatigue and trauma-associated hypoxia [2, 4, 15, 77] . Such physiological hypoxic stress is predicted to exacerbate tissue damage, to release infl ammatory mediators and BMPs, and to mobilize free radicals and the subsequent stimulation of mutant ACVR1/ALK2 in as yet unidentifi ed connective tissue progenitor cells that potentiate skeletal metamorphosis [76, [78] [79] [80] [81] [82] [83] [84] (Fig. 3) .
A major new area of FOP research is focused on the relationship of infl ammatory triggers, mutant ACVR1/ ALK2 receptors, and local environmental factors such as free radicals, pO 2 , and pH in the episodic fl are-ups of the disease [68, 75, 76, [78] [79] [80] [81] [82] [83] [84] . Recent protein modeling studies by Groppe et al. predict that the canonical FOP mutation creates a pH-sensitive switch within the cytoplasmic domain of the mutant ACVR1/ALK2 receptor that leads not only to ligand-independent activation but also to ligand-dependent hyper-responsiveness of mutant ACVR1/ ALK2 in the microenvironment of a lowered intracellular pH [68] .
Our working hypothesis on the pathophysiology of heterotopic skeletogenesis in FOP is that soft tissue injury creates an infl ammatory and acidic tissue microenvironment in which prostaglandins, free radicals, and hypoxia in concert with infl ammatory cells of hematopoietic origin stimulate resting connective tissue progenitor cells (CTPs) to become activated CTPs. These CTPs express the mutant ACVR1/ALK2 receptor that is putatively hyperactive in a mildly acidic intracellular environment and which results in misregulated BMP signaling through increased basal leakiness and conditional hyper-responsiveness to environmental BMPs [38] (Fig. 3) . Once formed, the fi broproliferative cells in the FOP lesion produce robust amounts of BMP4, and overactivity of the BMP signaling is suffi cient to drive the process of endochondral ossifi cation to completeness in the absence of a continued infl ammatory stimulus [38, 58] (see Fig. 3 ).
The recent discovery of the FOP gene mutation in all familial and sporadic cases of classic FOP suggests a cellautonomous basis for skeletal metamorphosis in FOP [61] . Protein modeling of the mutant receptor predicts destabilization of the GS activation domain consistent with basally leaky and conditional hyper-responsive BMP signaling as the cause of the ectopic chondrogenesis, osteogenesis, and joint fusion seen in FOP. Furthermore, these fi ndings allow us to hypothesize that trauma and infl ammation recruit osteogenic CTPs in which the activating mutation is expressed. These fi ndings are consistent with in vivo observations in animal models showing that once the endochondral anlagen is induced, abrogation of the infl ammatory response does not inhibit the formation of heterotopic bone [85] .
Interactions between infl ammatory cells and FOP mesenchymal cells in a microenvironment that is inductive and conducive to the initiation, progression, and sustenance of bone formation in FOP occurs at several steps (see Fig. 3 ). Recent studies have strongly suggested that migration of vascular progenitor cells to sites of infl ammation is a key step in normal and disordered regenerative responses and likely plays a role as well in the pathology of skeletal metamorphosis [85, 86] .
Stem cells and skeletal metamorphosis in FOP
Stem cells, progenitor cells, and infl ammation must therefore lie at the very heart of the process of metamorphosis (Fig. 3) . Hematopoietic cells have been implicated in the skeletal metamorphosis of FOP, and their replacement has been postulated as a possible cure [85] . However, the defi nitive contribution of hematopoietic cells to the pathogenesis of skeletal metamorphosis has, until recently, remained obscure. A recent study in a patient with FOP who coincidentally developed intercurrent aplastic anemia demonstrated that bone marrow transplantation does not cure FOP. However, following transplantation of bone marrow from a normal donor, immunosuppression of the immune system appeared to ameliorate activation of skeletal metamorphosis in a genetically susceptible host. Thus, cells of hematopoietic origin may contribute to and perhaps even trigger the formation of an ectopic skeleton, although they are not suffi cient to complete the process alone. Moreover, even a normal functioning immune system is apparently suffi cient to trigger an FOP fl are-up in a genetically susceptible host [85] . Which cells contribute to the fi broproliferative and chondrogenic mesenchymal anlagen in skeletal metamorphosis? The question is fascinating, important, and unresolved. Recent studies performed with two independent routes of investigation support the contention that such cells are not of hematopoietic origin, but arise from a different pool of connective tissue progenitor (CTP) cells residing in skeletal muscle and associated connective tissues, with possible lineage origins in endothelial cells, smooth muscle cells, neural cells, or other CTP cells [85] . Therefore, multiple sources of pluripotent stem cells or progenitors may contribute to the formation of an ectopic skeleton in the process of skeletal metamorphosis [85] . Detailed lineage-tracing experiments in transgenic mice with stable lineage markers will be necessary to defi nitively determine the origin of these cells. The development of a knock-in mouse that replicates the identical mutation of classic FOP is presently underway and will facilitate the identifi cation of the autonomous connective tissue progenitor cell(s) that contribute to dysregulated BMP signaling in FOP.
Taken together, skeletal metamorphosis appears to be a stem cell or progenitor cell disorder, triggered by infl ammation. One normal tissue is replaced with another, but fi rst, nearly all vestiges of the original tissue, except its soft tissue scaffolding, neurovascular infrastructure, and progenitor cell repository, are destroyed and then replaced with a different tissue and a different epigenetic identity. Recent studies in FOP suggest that connective tissue progenitor cells resident in the local tissues are responsible for this metamorphosis, although the process is triggered by local infl ammatory signals [75, 85] . Essentially, skeletal metamorphosis is a disorder of dysregulated tissue repair. Metamorphosis thus unmasks the deep developmental restraints that must exist in normal tissue repair, and which are liberated, to the detriment of the host, by the specifi c recurrent mutation in the ACVR1/ALK2 (R206H) metamorphogene [3, 85] .
Prevention and treatment of skeletal metamorphosis in FOP
Presently, medical intervention for FOP is supportive. Guidelines for symptomatic management of disease fl areups have been published and highlight the anecdotal utility of glucocorticoids in managing new fl are-ups affecting the function of major joints in the appendicular skeleton [87] . Nonsteroidal antiinfl ammatory medications, COX-2 inhibitors, leukotriene inhibitors, and mast cell stabilizers are useful anecdotally in managing chronic discomfort and ongoing fl are-ups, but presently there is no proven effi cacy with any therapy in altering the natural history of the disease [87] . The rarity, variable severity, and episodic clinical course of FOP pose substantial uncertainties when evaluating experimental therapies [87] . A recent report documented the failure of bone marrow transplantation to cure the condition, but suggested that chronic immunosuppression may have some utility, although its general use is not recommended [85] .
Surgical release of joint contractures is generally unsuccessful and risks new, trauma-induced heterotopic ossifi cation. Osteotomy of heterotopic bone or surgical removal of heterotopic bone to mobilize joints is generally counterproductive because additional heterotopic ossifi cation develops at the operative site. Rarely, a joint may be repositioned surgically to improve the patient's overall functional status. Spinal bracing is ineffective, and surgical intervention is associated with numerous complications [88] .
The ultimate goal of FOP research is the development of treatments that will prevent, halt, or even reverse the progression of the condition. The prevention and treatment of heterotopic ossifi cation in FOP, as in any of the more common forms of heterotopic ossifi cation, will ultimately be based on at least one of four principles: disrupting the relevant inductive signaling pathways, blocking the immunological and/or infl ammatory triggers, suppressing the relevant osteoprogenitor cells in the target tissues, and modifying the tissue environment conducive to heterotopic osteogenesis (Fig. 4) .
The identifi cation of the recurrent heterozygous missense point mutation that causes FOP in all classically affected individuals provides a specifi c druggable target and a rational point of intervention in a critical signaling pathway [89] . Plausible therapeutic approaches to inhibiting BMP signaling in FOP include inhibitory RNA technology, monoclonal antibodies directed against ACVR1/ALK2, and orally available small molecule selective signal transduction inhibitors (STIs) of ACVR1/ALK2 [89] , such as Dorsomorphin or its derivatives [90] which inhibit hetero-topic ossifi cation in infl ammation-induced models of BMP pathway overactivity.
Metamorphosis and tissue engineering: harnessing the FOP metamorphogene ACVR1/ALK2 (R206H) is the fi rst identifi ed human metamorphogene and provides a genetic basis for understanding the general biological principles that orchestrate the pathological transformation of one normal organ system into another. The immediate goal of FOP research is to understand the molecular and cellular pathophysiology of this process and to use that knowledge to develop pharmacological methods to block and prevent it. Conversely, it may be possible to harness the gene mutation that causes FOP to create new skeletal elements in a controlled way-for patients who have osteoporotic fractures, for those with severe bone loss from trauma or neoplasms, for those with fractures that fail to heal, for those with spinal fusions that are slow to heal, or for those with congenital malformations of the spine and limbs who need new bone. The discovery of the FOP gene, the fi rst human metamorphogene, is a monumental milestone in an epic journey to understand the biological principles that regulate tissue stability and skeletal metamorphosis following embryogenesis.
Other examples of skeletal metamorphosis in humans
Classic FOP and its phenotypic and genotypic variants are the most dramatic, but not the only, examples of skeletal metamorphosis in humans. There are, for example, many acquired forms of skeletal metamorphosis that are spatially and temporally limited. Some are fairly common, such as the heterotopic ossifi cation that occurs following closed head injury, spinal cord injury, total hip replacement, athletic injury, and blast injuries from war [18, [91] [92] [93] [94] . Additionally, approximately 13% of individuals with end-stage valvular heart disease form mature heterotopic bone in the aortic valve [91] . To date, there are few studies on the molecular pathogenesis in these more common disorders of skeletal metamorphosis. Where it has been examined, the histology is similar in all, and it would not be surprising if the ACVR1/ALK2 signaling pathway was involved in the more common as in the rarer forms of skeletal metamorphosis.
Nature does not use different genes, molecules, and pathways for common conditions or for rare ones. Rather, it is often the rare disease that reveals which gene, molecule, or pathway nature hijacks in its common infi rmities [95] . William Harvey, the discoverer of the circulatory system, wrote in 1657:
"Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature by the careful investigation of cases of rarer forms of disease." [96] 
